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ABSTRACT Small airway and interstitial pulmonary involvements are prominent in chronic
hypersensitivity pneumonitis (cHP). However, their roles on exercise limitation and the relationship with
functional lung tests have not been studied in detail.
Our aim was to evaluate exercise performance and its determinants in cHP. We evaluated maximal
cardiopulmonary exercise testing performance in 28 cHP patients (forced vital capacity 57±17% pred) and
18 healthy controls during cycling.
Patients had reduced exercise performance with lower peak oxygen production (16.6 (12.3–19.98)
mL·kg−1·min−1 versus 25.1 (16.9–32.0), p=0.003), diminished breathing reserve (% maximal voluntary
ventilation) (12 (6.4–34.8)% versus 41 (32.7–50.8)%, p<0.001) and hyperventilation (minute ventilation/
carbon dioxide production slope 37±5 versus 31±4, p<0.001). All patients presented oxygen desaturation
and augmented Borg dyspnoea scores (8 (5–10) versus 4 (1–7), p=0.004). The prevalence of dynamic
hyperinflation was found in only 18% of patients. When comparing cHP patients with normal and low
peak oxygen production (<84% pred, lower limit of normal), the latter exhibited a higher minute
ventilation/carbon dioxide production slope (39±5.0 versus 34±3.6, p=0.004), lower tidal volume (0.84
(0.78–0.90) L versus 1.15 (0.97–1.67) L, p=0.002), and poorer physical functioning score on the Short
form-36 health survey. Receiver operating characteristic curve analysis showed that reduced lung volumes
(forced vital capacity %, total lung capacity % and diffusing capacity of the lung for carbon dioxide %)
were high predictors of poor exercise capacity.
Reduced exercise capacity was prevalent in patients because of ventilatory limitation and not due to
dynamic hyperinflation. Reduced lung volumes were reliable predictors of lower performance during exercise.
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Hypersensitivity pneumonitis is an interstitial lung disease (ILD) with variable clinical symptoms, caused
by inhalation of specific organic antigens or low-molecular weight substances in genetically susceptible
individuals [1–4]. Chronic hypersensitivity pneumonitis (cHP) represents the final stage of the disease, in
which prolonged antigenic exposure causes lung fibrosis.
A unique feature of hypersensitivity pneumonitis is some degree of abnormality within and/or around the
small airways, observed to be present in all patients with hypersensitivity pneumonitis in histopathology
[5] and in some patients when evaluated by pulmonary functional tests (PFTs) [6]. Computed tomography
(CT) scans have provided evidence for small airway disease in cHP, suggested by mosaic attenuation
pattern, air trapping on expiratory scans, centrilobular ground-glass opacities and the absence of
predominance in inferior lobes [7–9].
Few studies have assessed exercise capacity in cHP patients [10, 11]; however, the mechanisms underlying
these exercise limitations were not properly evaluated. One study evaluating patients with farmer’s lung
acutely exposed to mould showed an increased alveolar–arterial gradient, increased dead space and
decreased ventilatory reserve at the end of cardiopulmonary exercise testing (CPET) [11]. Another
investigation evaluated the prevalence of pulmonary hypertension in cHP patients using haemodynamic
evaluation, and CPET was performed as a complimentary test [10]. Oxygen uptake (V′O2) at peak exercise
and the anaerobic threshold were significantly lower in patients with pulmonary hypertension; however,
no significant differences were found in any other CPET parameter [10]. Since cHP is initially
characterised by airway involvement and later by interstitial fibrosis, exercise limitations may potentially be
secondary to: 1) airway obstruction with dynamic hyperinflation (DH); and/or 2) significant oxygen
desaturation and small tidal volume (VT) increment.
The presence of DH has been confirmed in several studies in moderate-to-severe chronic obstructive
pulmonary disease (COPD) and is strongly related to augmented dyspnoea [12–14]. DH is also prevalent
in lymphangioleiomyomatosis (LAM), an ILD, and is associated with exercise limitations and increased
breathlessness [15]. In other ILDs, small numbers of studies have indicated that inspiratory capacity (IC)
throughout exercise remains largely unaltered [16, 17], while others have found expiratory flow limitation
during exercise [18]. Elucidating the prevalent mechanisms underlying exercise limitations in cHP might
have a large impact on treatment decisions.
Therefore, we aimed to: 1) determine the exercise capacity and mechanisms of exercise impairment in cHP
patients compared to healthy subjects; 2) evaluate the presence of DH through IC manoeuvers during
maximal incremental CPET; and 3) compare cHP patients with normal and impaired exercise
performance and investigate predictive functional values for worse exercise response.
Materials and methods
Study subjects
This study is part of a comprehensive study evaluating small airway involvement in cHP patients (www.
ClinicalTrials.gov identifier NCT 02523833) with volumetric CT scans, PFTs and CPET. From September
2015 to March 2017, 178 patients with a confirmed cHP diagnosis, followed at the ILD outpatient clinic of
the Pulmonary Division of the Hospital das Clínicas of the University of São Paulo, São Paulo, Brazil, were
prospectively evaluated and 28 were enrolled (figure 1). cHP diagnosis was defined on CT findings
(fibrotic involvement of the pulmonary parenchyma), known antigenic exposure, exclusion of other
possible diagnoses, and compatible histology upon transbronchial or open lung biopsy, or bronchoalveolar
lavage with lymphocytosis >30%. Exclusion criteria are detailed in the supplemental material. 18
age-matched healthy, nonsmoking subjects (mean age: 54±12.8 years, forced vital capacity (FVC) 89%
Exclusion criteria:
28 patients smoking history >20 pack-years
22 patients with comorbidities or unable to
     perfom tests
13 patients lost to follow-up
53 patients under supplementary oxygen
28 patients aged >75 years
5 patients with DLCO or FVC <30% pred





FIGURE 1 Study recruitment protocol. cHP: chronic hypersensitivity pneumonitis; DLCO: diffusing capacity of the lung
for carbon monoxide; FVC: forced vital capacity.
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predicted) were also studied as a control group. The study protocol was approved by the local research
ethics committee (SDC 3966/13/091), and all patients signed informed consent.
Measurements
Dyspnoea and quality of life were assessed using the modified Baseline Dyspnoea Index and the Short
form-36 health survey (SF-36) questionnaire, which has been validated for the Brazilian population [19, 20].
Pulmonary function tests
PFTs were performed following European Respiratory Society/American Thoracic Society guidelines
[21–23]. Spirometry was performed using a calibrated pneumotachograph (Medical Graphics Corporation,
St. Paul, MN, USA). Lung volumes and diffusing capacity of the lung for carbon dioxide (DLCO) were
measured with a body plethysmograph (Elite Dx, Elite Series; Medical Graphics Corporation). FVC, forced
expiratory volume in 1 s (FEV1), total lung capacity (TLC), residual volume (RV), and DLCO were
obtained. Subsequently, all patients received salbutamol (400 µg) and repeated the same variables
measured in baseline spirometry. Predicted values were derived from the Brazilian population [24, 25].
Cardiopulmonary exercise testing
All patients underwent incremental, ramp type CPET on a cycle ergometer (model VIA Sprint 150P;
CareFusion, San Diego, CA, USA), up to the tolerance limit or if presented any reason for interruption. The
CPET protocol consisted of a symptom-limited incremental exercise test, including 2 min without pedalling,
a warm-up period of 2 min (free wheel (FW)) followed by a progressively increasing work rate in a ramp
fashion (5–15 W·min−1), and then a 3-min recovery phase. The incremental rate was selected according to
the physical fitness and pulmonary functional evaluation of each patient, aiming at test duration of 8–12 min.
The system used was the Vmax Encore CPET (VIASYS CareFusion), which is composed of a gas analyser
coupled to a flow module through a mouthpiece. An integrated 12-lead electrocardiogram (Cardio Perfect
PC-based 12 lead ECG; Welch Allyn, INC., Skaneateles Falls, NY, USA) was registered and peripheral
oxygen saturation, using the NONIN oximeter (Onyx model 9500; Nonin Medical, INC., Plymouth, MN,
USA), was continuously measured. The reference values used are those proposed for the Brazilian
population by NEDER et al. [26]. Aerobic capacity was considered normal if values of V′O2 max were ⩾84%
pred [27]. Discomfort in the lower limbs and dyspnoea intensity were assessed before the test, every 2 min
and at the end of the test using the modified Borg scale [28]. Maximal exercise was determined if patients
reached 85% of predicted maximal heart rate, had no ventilatory reserve or significant oxygen desaturation
(<80%) or respiratory exchange rate >1.15.
Measured variables and test interruption criteria are detailed in the supplemental material. To evaluate the
presence of DH, the IC was measured at the end of expiration at rest and every 2 min. The end expiratory
lung volume was obtained indirectly by the difference in the TLC by the IC [29, 30]. Two reproducible
manoeuvers were performed at each moment, with a difference <150 mL, and the highest value was
adopted. The occurrence of DH was defined as IC variations of at least 10% from baseline [30].
Statistical analysis
Data are presented as mean±SD for normally distributed variables or as median (25th–75th percentiles) for
non-normally distributed variables. Unpaired t-tests or the Mann–Whitney U-test were used to compare
continuous variables between normal subjects and cHP patients, and in-between cHP patients.
A two-way repeated measures ANOVA was used to analyse time course differences of the variables with
normal distribution and to evaluate differences between groups. The receiver operating characteristic
(ROC) curve was used to identify lung function parameters (% predicted) with the best accuracy for
predicting reduced exercise performance (V′O2 <84% pred) in cHP patients. Signiﬁcance was set at p<0.05.
Statistical analyses were performed using SPSS version 21.0 (IBM Corp, Armonk, NY, USA).
Results
Baseline patient characteristics
The general characteristics of cHP patients and healthy subjects paired by age, sex, and body mass index
are presented in table 1. All but four cHP patients had restrictive lung disease; however, all had reduced
DLCO. Only three patients had a RV/TLC ratio >0.40 plus RV >140% pred, consistent with concomitant
air trapping. None had bronchodilator response to salbutamol. At the time of the study, 18 patients were
receiving treatment and 10 had previously received immunosuppressors. Additionally, 25 (89%) received
or were receiving corticosteroids, and 13 (46%) received or were receiving cytotoxic drugs.
Pulmonary biopsy was performed in 78% of patients and bronchoalveolar lavage in 75%. From biopsied
patients, 17 underwent transbronchial biopsy. The main findings were chronic lymphocytic bronchiolitis
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(n=13), bronchiolar metaplasia (n=2), classic pattern with chronic cellular bronchiolitis and the presence
of malformed granulomas (n=1); in one transbronchial biopsy, material was not representative. Among
five patients that underwent open lung biopsy, four patients had nonspecific interstitial pneumonia pattern
associated with bronchiolocentric fibrotic involvement and one patient presented the classic histological
hypersensitivity pneumonitis triad (chronic interstitial pneumonia with peribronchiolar accentuation,
bronchiolitis and non-caseating granulomas).
TABLE 1 Baseline characteristics of patients with chronic hypersensitivity pneumonitis (cHP)
and healthy subjects
cHP Healthy subjects
Subjects n 28 18
Females 16 (57.1) 10 (55.6)
Age years 56±11.5 54±12.8
BMI kg·m−2 27.2 (25.4–30.4) 26.6 (23–28)
Baseline dyspnoea index mMRC 1 (1–2)
Smokers 8 (29)





Weight loss 11 (38)




Feather pillow 6 (21)
Others 3 (11)
No recognised exposure 0 (0)
Actual exposure/previous exposure n 4/24
Pulmonary function tests
FVC L 2.03±0.65 3.33±0.85*
FVC % pred 57±17 89±10*
FEV1 L 1.75±0.52 2.74±0.62*




TLC % pred 64 (53–72)
RV L 1.18 (1.06–1.47)
RV % pred 77 (60–88)
RV/TLC 0.39±0.07
DLCO % pred 42 (31–63)
HRCT findings
Centrilobular nodules 3 (11)
Ground-glass opacities 26 (96)
Mosaic pattern 15 (54)
Honeycombing 4 (14)
Findings suggestive of fibrosis 25 (89)
Emphysema 0 (0)
Bronchoalveolar lavage 21 (75)
Lymphocyte count 23 (10–38)
CD4/CD8 ratio 0.57 (0.37–1.29)
Lung biopsy 21 (78)
Transbronchial 16 (59)
Surgical 5 (19)
Data are presented as n (%), mean±SD if normally distributed or median (25th–75th percentile), unless
otherwise stated. BMI: body mass index; mMRC: modified Medical Research Council; FVC: forced vital
capacity; FEV1: forced expiratory volume in 1 s; FEF25–75%: forced expiratory flow at 25–75% of FVC; TLC:
total lung capacity; RV: residual volume; DLCO: diffusing capacity of the lung for carbon monoxide; HRCT:
high-resolution computed tomography. *: p<0.05.
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CPET for healthy subjects and cHP patients
Table 2 shows CPET data at peak exercise. cHP patients had diminished exercise performance
(workload and oxygen consumption) compared to healthy subjects. Considering the ventilatory
responses, the final breathing reserve (% maximal voluntary ventilation) was significantly reduced in
cHP patients and they also demonstrated a greater respiratory rate with lower VT, in the presence of
increased ventilatory response (higher minute ventilation (V′E)/carbon dioxide production (V′CO2)
slope) during exercise. Concerning cardiovascular responses, cHP patients achieved lower heart
rates and obtained lower oxygen pulse. However, no patient presented evidence of cardiovascular
limitations, including pulmonary hypertension with early plateau in oxygen pulse or a significant
decrease in end-tidal carbon dioxide tension (mmHg) during the test. Finally, all but two cHP patients
presented significant oxygen desaturation during exercise (desaturation >4% compared to baseline
levels), and 46% interrupted the CPET due to significant desaturation (arterial oxygen saturation
<80%). Increased breathlessness (augmented Borg dyspnoea score) and dyspnoea (93%) were the major
reasons for CPET interruption.
Figure 2 illustrates V′E, VT and dyspnoea (Borg scale) responses paired to workload during the exercise
test in cHP patients compared with controls. V′E was significantly higher in controls when compared with
patients for all workloads (p<0.05). VT also significantly differed during FW, 40 W and at peak exercise
(p<0.05). Dyspnoea scores were higher in cHP patients; however, this difference was not statistically
significant. No patient presented complications resulting in early interruption of the test.
Only one cHP patient was unable to perform acceptable IC manoeuvers according to the protocol and
thus was excluded from the analysis. No statistically significant difference in IC variation between healthy
and cHP patients was observed. Regarding the remaining 27 patients during CPET, five (18%) had an IC
decrease >10% during exercise, which is consistent with DH, whereas this was not observed in any control
participant. The IC variation in relation to workload at peak effort compared to baseline levels in
percentage and litres is illustrated in figure E1. We found that three cHP patients with DH had normal
exercise capacity and only two had lower exercise capacity.
TABLE 2 Incremental cardiopulmonary exercise testing on a cycle ergometer (peak exercise
data) in patients with chronic hypersensitivity pneumonitis (cHP) and healthy subjects
cHP Healthy subjects p-value
Subjects n 28 18
Exercise time min 7.24±3.02 7.17±2.05 0.89
RER 1.04±0.14 1.08±0.13 0.30
Work rate W 66±35 138±69 <0.001
Work rate % pred 53±23 104±35 <0.001
V′O2 mL·kg−1·min−1 16.6 (12.3–19.98) 25.1 (16.9–32.0) 0.003
V′O2 %pred 83 (63–97) 112 (89–118) <0.001
V′E L·min−1 50 (42–63) 71 (45–89) 0.05
Breathing reserve % MVV 12 (6.4–34.8) 41 (32.7–50.8) <0.001
V′E/V′CO2 slope 37±5 31±4 <0.001
VT L 0.91 (0.82–1.25) 1.75 (1.29–2.21) <0.001
Respiratory rate breaths·min−1 52±11 40±10 0.001
VT/IC 0.77±0.15 0.68±0.16 0.06
ΔPETCO2 mmHg -0.24±2.67 -0.11±2.83 0.88
HR beats·min−1 133±20 149±26 0.03
HR % pred 84 (75–89) 95 (88–99) 0.008
V′O2/HR mL·beat−1·min−1 9.5±2.9 12.6±5.0 0.01
V′O2/HR % pred 93±19 122±29 <0.001
SpO2 % 81±7 95±2 <0.001
Borg dyspnoea score 8 (5–10) 4 (1–7) 0.004
Borg leg discomfort score 8 (4–9) 7 (4–9) 0.71
ΔIC from rest L -0.01±0.20 0.11±0.25 0.08
ΔIC from rest % 1.92±12 4.96±11 0.43
Data are presented as mean±SD or median (25th–75th percentile), unless otherwise stated. RER:
respiratory exchange rate; V′O2: oxygen production; V′E: minute ventilation; MVV: maximal voluntary
ventilation; V′CO2: carbon dioxide production; VT: tidal volume; IC: inspiratory capacity; PETCO2: end-tidal
carbon dioxide tension; HR: heart rate; SpO2: arterial oxygen saturation measured by pulse oximetry.
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Exercise data of cHP patients with normal and low exercise capacity
Table 3 shows CPET data at peak exercise comparing cHP patients to controls (V′O2 ⩾84% pred) and low
peak V′O2. Dyspnoea interrupted exercise in all but two patients in the normal exercise capacity subgroup.
As expected, patients with low peak V′O2 had lower exercise performance, and also significantly higher
V′E/V′CO2 slope and lower VT. Differences were also observed in this subgroup with reduced oxygen pulse
and heart rate. No differences were seen in all other exercise variables, including IC variation and VT/IC.
Patients with normal exercise capacity had more preserved lung volumes, FEV1 and DLCO (table 4).
The ROC curve analysis showed that the FVC (% pred) with the highest accuracy to predict reduced
exercise capacity was 58.5% (area under the curve (AUC) 0.824, 95% CI 0.67–0.98, p=0.004;
sensitivity and specificity of 78.6%). Also, a TLC (% pred) of 58.5% (AUC 0.806, 95% CI 0.64–0.97,
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Rest FW 20 40 Peak
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FIGURE 2 a) Minute ventilation (V′E), b) tidal volume (VT) and c) dyspnoea (Borg score) paired to workload during an incremental cycle exercise test in
patients with chronic hypersensitivity pneumonitis (cHP) compared to age-matched healthy controls. V′E and dyspnoea intensity were higher in cHP
patients at any given work rate, whereas VT was higher in controls at free wheel (FW), 40 W and peak exercise. Dyspnoea scores were higher in cHP
patients, although this difference was not significant. Data are presented as mean±SEM. *: p<0.05, **: p<0.005 for cHP patients versus controls.
TABLE 3 Incremental cardiopulmonary exercise on a cycle ergometer (peak exercise data) in
patients with chronic hypersensitivity pneumonitis
V′O2 ⩾84% pred V′O2 <84% pred p-value
Subjects n 14 14
Exercise time min 8.4±2.4 6.0±2.5 0.02
Work rate W 83.4±36 47.86±24 0.005
Work rate %pred 70.0±17 36.0±15 <0.001
V′O2 mL·min−1·kg−1 20.51±6.42 20.51±6.42 0.006
V′O2 % pred 99±12 63±11 <0.001
ΔPETCO2 mmHg 0.06±2.39 -0.53±2.99 0.56
RER 1.04±0.12 1.03±0.16 0.81
V′E/V′CO2 slope 34±3.6 39±5.0 0.004
V′E L·min−1 57 (47–78) 44 (40–54) 0.04
Breathing reserve %MVV 11 (6.6–26.3) 22 (1.0–40.7) 0.60
VT L 1.15 (0.97–1.67) 0.84 (0.78–0.90) 0.002
Respiratory rate breaths·min−1 49±8 54±12 0.21
HR beats·min−1 139±13 128±23 0.12
HR % pred 88±7 78±12 0.009
V′O2/HR mL·beat−1·min−1 10.8±3.1 8.2±2.0 0.02
V′O2/HR % pred 107±11 80±13 <0.001
SpO2 % 83±6 79±8 0.10
Borg dyspnoea score 5 (4–9) 9 (5–10) 0.13
Borg leg discomfort score 7 (5–9) 9 (2–9) 0.91
ΔIC from rest L -0.01±0.27 -0.02±0.12 0.94
ΔIC from rest % 2.5±16 1.4±9 0.81
VT/IC 0.80±0.13 0.75±0.17 0.40
Data are presented as mean±SD or median (25th–75th percentile), unless otherwise stated. V′O2: oxygen
production; PETCO2: end-tidal carbon dioxide tension; RER: respiratory exchange rate; V′E: minute
ventilation; V′CO2: carbon dioxide production; MVV: maximal voluntary ventilation; VT: tidal volume; HR:
heart rate; IC: inspiratory capacity; SpO2: arterial oxygen saturation measured by pulse oximetry.
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p=0.006; sensitivity 92.9%, specificity 64.3%) and a DLCO (% pred) of 30.0% (AUC 0.778, 95% CI
0.60–0.96, p=0.02; sensitivity 100%, specificity 46.2%) predicted normal exercise capacity (figure 3).
Table 5 compares responses to the SF-36 survey between cHP patients with normal and low exercise
capacity. As expected, cHP patients with low exercise capacity had lower physical functioning scores
(55±27 versus 36±20, p=0.05) and a tendency towards lower scores in role limitation due to physical
health (p=0.09) and vitality (p=0.06). No differences were observed in other domains.
Discussion
Our study aimed to evaluate the exercise capacity and the mechanisms underlying exercise limitation,
including the development of DH in patients with cHP. Thus, we compared time course responses of the
cardiopulmonary and metabolic systems with those of healthy controls. The main findings of our study
were: 1) exercise capacity is lower in cHP patients than in healthy subjects; 2) ventilatory limitation and
gas exchange impairment with increased dyspnoea were the major reasons for exercise cessation in cHP
patients; 3) the prevalence of DH during exercise in cHP patients is low, and without clinically significant
TABLE 4 Pulmonary function in patients with chronic hypersensitivity pneumonitis
V′O2 ⩾84% pred V′O2 <84% pred p-value
Subjects n 14 14
FVC L 2.22±0.60 1.85±0.66 0.13
FVC % pred 62 (58–70) 45 (41–59) 0.002
FEV1 L 1.88±0.45 1.62±0.56 0.20
FEV1 % pred 70±13 53±14 0.003
FEV1/FVC 0.86±0.06 0.89±0.04 0.14
FEV1/FVC % pred 106 (105–113) 108 (105–115) 0.54
FEF25–75% 101±29 95±34 0.65
TLC L 3.67 (3.00–4.17) 2.92 (2.43–3.59) 0.14
TLC % pred 69 (62–77) 55 (49–67) 0.005
RV L 1.33 (1.10–1.52) 1.15 (0.98–1.38) 0.25
RV % pred 78 (69–91) 76 (56–86) 0.35
RV/TLC 0.37±0.06 0.41±0.07 0.21
RV/TLC % pred 131±29 151±45 0.17
DLCO % pred 50 (38–71) 33 (26–45) 0.01
Data are presented as mean±SD or median (25th–75th percentile), unless otherwise stated. V′O2: oxygen
production; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; FEF25–75%: forced expiratory
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FIGURE 3 Receiver operating characteristic curve for a) forced vital capacity (% predicted), b) total lung capacity (% predicted) and c) diffusing
capacity of the lung for carbon dioxide (% predicted) for predicting normal exercise capacity in chronic hypersensitivity patients. AUC: area under
the curve.
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repercussions; and 4) these findings during exercise are related to disease severity, and lung volumes and
DLCO are good predictors of exercise limitation.
cHP patients had diminished exercise performance and lower V′O2 compared to normal subjects, which
was mainly due to ventilatory limitations and gas exchange impairment. Reduced exercise performance
occurred in half of our patients. cHP patients presented with reduced breathing reserve and a greater
V′E/V′CO2 slope, oxygen desaturation in all but two patients and increases in V′E based on respiratory rate,
with a small increment of VT, which is in accordance with the restrictive pattern found in patients with
ILD [31]. In heathy subjects, the expansion of VT during exercise is accommodated within the most
compliant, linear portion of the respiratory system’s pressure–volume relationship [32] and the
effort–displacement ratio remains relatively constant during exercise [33]. In cHP, as in other ILDs, the
respiratory system’s pressure–volume curve is contracted along its volume axis and is shifted downward
and rightward, indicating increased elastic recoil pressure of the lung at any given lung volume [34, 35].
Severe dyspnoea, as demonstrated by higher Borg scores, was the dominant exercise-limiting symptom in
these patients. cHP patients had a lower heart rate and an oxygen pulse than healthy subjects, probably
caused by precocious interruption of exercise due to ventilatory limitation and/or oxygen desaturation,
since no patient had evidence of cardiovascular limitation or pulmonary arterial hypertension, such as
high V′E/V′CO2 or low partial pressure of end-tidal carbon dioxide at the end of the exercise [36].
Although our protocol excluded patients with pulmonary hypertension, it is not possible to completely
rule it out as a possible limiting factor as hypersensitivity pneumonitis may present pulmonary
hypertension even in the presence of a normal echocardiograph [10, 37, 38]. Additionally, CPET is not a
reliable predictor of pulmonary hypertension in these patients [10].
Two patients in our study had significant chronotropic and ventilatory reserve without other reasons for
exercise limitation, justifying peripheral muscle dysfunction. However, we emphasise that besides the high
prevalence of corticosteroids in our cohort and its potential role in exercise limitation as previously
described in ILD patients [39], 93% of our patients interrupted exercise due to dyspnoea, with diverse
indexes of ventilatory limitation, which reinforces that peripheral muscle dysfunction was not the prevalent
mechanism for exercise cessation in these patients.
Although the prevalence of DH in our sample was 18%, no difference in IC variation was observed
between healthy and cHP patients or between cHP subgroups (normal versus low exercise capacity),
suggesting that DH is not a relevant mechanism for the exercise limitations in these patients. The
explanation for IC variation in cHP remains to be elucidated.
One potential mechanism may be due to DH per se secondary to small airway involvement. Although
PFTs showed restrictive lung disease in all but two patients, the RV/TLC ratio in our entire cohort was
141±38% pred, which could suggest concomitant small airway involvement. Also, besides signs of small
airway involvement in all biopsied patients and the presence of mosaic attenuation on CT in 54% of the
entire cohort, patients had severe restrictive impairment, and only three patients had physiological signs of
air trapping. The exact prevalence of obstructive disorder in cHP is unknown; it is higher in hot tub lung
disease [40] and farmer’s lung [41], but also reduces progressively the longer the diagnosis, probably
TABLE 5 Short form-36 health survey data from patients with chronic hypersensitivity
pneumonitis
V′O2 ⩾84% pred V′O2 <84% pred p-value
Subjects n 14 14
Physical component scores
Physical functioning 55±27 36±20 0.05*
Role limitation due to physical health 50 (0–75) 0 (0–25) 0.09
Bodily pain 79 (45–100) 68 (48–83) 0.43
General health 63 (39–90) 45 (34–69) 0.15
Mental component scores
Role limitation due to emotional problems 17 (0–100) 33 (0–100) 0.73
Vitality 65±25 50±14 0.06
Emotional well-being 70±21 63±19 0.38
Social functioning 75±22 69±25 0.48
Data are presented as mean±SD or median (25th–75th percentile), unless otherwise stated. V′O2: oxygen
production. *: p<0.05.
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reflecting the evolution of fibrosis [42]. Our patients had a median time after diagnosis of 24 months,
which could have contributed to our results. It is likely that in our cohort of patients the influence of DH
is milder, and the increased elastic recoil component prevails functionally and during exercise; besides,
traction bronchiectasis may have attenuated air trapping caused by airway lesions. In patients with milder
restriction and severe air trapping, DH may have a greater influence in exercise limitation. Due to the
small number of patients with DH, we could not explore lung function parameters or CPET data to
determine predictive data for its occurrence.
A second mechanism may be mechanical factors and decreased inspiratory muscle performance. We
observed a tendency towards higher VT/IC in cHP patients (p=0.06). In this context, a limitation of
increased IC may have increased elastic recoil in restrictive lung disease. In these patients, increased
breathing effort and respiratory muscle fatigue at greater V′E may be an explanation for IC reduction. Due
to the exploratory nature of our study, and lack of oesophageal pressure measurements, the role of this
mechanism remains to be fully elucidated.
ILDs can present significant airway involvement and DH can be one of the mechanisms for exercise
limitation, such as in patients with LAM [15]. In pulmonary Langerhans cell hystiocytosis patients, the “air
trapping” component seemed to limit patients during exercise, as assessed by a lower FEV1/FVC ratio in
patients with impaired exercise capacity; however, flow–volume loops were not performed in this study
[43]. In sarcoidosis, in which ventilatory and cardiocirculatory impairment may occur, inspiratory
manoeuvers during CPET have not been assessed. In LAM, DH had an intrinsic relationship with airway
obstruction detected by pulmonary function tests. In ILD, we postulate that DH occurrence might also have
a close relationship with airway obstruction, which may explain the low prevalence of DH in our study.
cHP patients with low exercise capacity were unable to increase their tidal ventilation compared to patients
with normal exercise capacity, without differences in oxygenation, respiratory rate or breathing reserve.
Also, breathing reserve alone was not a good predictor of ventilatory limitation in these patients, as
previously shown in mild COPD [44]. Thus, the main factor for low exercise capacity in these patients
seems to be disease severity assessed by PFTs parameters. Patients with normal exercise capacity had
increased FVC %, FEV1 %, TLC % and DLCO %. For the first time, we could accurately determine the
values of PFTs and predict worse exercise capacity in cHP. Based on the ROC curve analysis, the best
predictor for worse exercise capacity was FVC (% pred), and the value with the highest accuracy was
58.5%, followed by a TLC of 58.5% pred and a DLCO of 30% pred. FVC is an easily available parameter in
clinical practice. In the context of ILDs, functional tests, especially during exertion, can be important tools
for treatment evaluation, follow-up and prognosis. However, the current literature is extrapolated from
patients with idiopathic pulmonary fibrosis (IPF), with submaximal tests such as the 6-min walk distance
[45, 46]. To our knowledge, our study is the first to characterise functional data with preserved exercise
capacity in cHP patients.
According to previous publications, a low DLCO, measured at rest, is the most significant predictor of
exertional hypoxaemia in previous publications with fibrotic ILD; of note, fibrotic ILD patients have more
severe exertional hypoxaemia than patients with COPD for a given degree of impairment in DLCO [47]. In
ILD patients, it is also known that a substantial number of patients with normal DLCO have increased
desaturation at maximal exercise, suggesting that normal DLCO at rest may be an inappropriate predictor
of abnormal pulmonary gas exchange during exercise. We strongly believe that in exercise, unequal
ventilation/perfusion rates in fibrotic lung parenchyma and low ventilatory efficiency (high V′E/V′CO2) can
contribute to a significant oxygen desaturation besides the degree of DLCO impairment measured at rest.
Of note, it is also important to emphasise that although we hypothetically excluded pulmonary
hypertension in our patients according to the study protocol, it is still possible it could have contributed to
additional desaturation in our study.
cHP patients with low exercise capacity had lower physical functioning scores and a tendency towards lower
scores in physical health and vitality. Other domains did not have significant differences between cHP groups.
Studies assessing quality of life (QoL) in cHP are still emerging. A previous study reported that cHP patients
had worse QoL scores when compared with IPF patients and the severity of dyspnoea and fatigue were the
strongest factors associated with a poor QoL [48]. Our study confirmed that worse exercise capacity
significantly impacted on physical score domains. However, other factors, such as socioeconomic support,
physical and mental comorbidities, and cultural differences could also have a greater impact in other
domains. Since QoL is increasingly being considered as a patient-centred outcome measure in ILD clinical
trials [48–50], interventions such as rehabilitation programmes might significantly impact QoL in
these patients.
Our study has some limitations that need to be addressed. Due to our strict inclusion criteria, our sample
size was relatively small. Furthermore, our patient cohort was composed of patients with a low smoking
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burden. Heavy smokers were intentionally excluded to avoid confounding our results due to small airway
involvement associated with smoking. Also, our cohort is not comprised of patients with obstructive
disease and our results can only be extrapolated to patients with restrictive disease, which can explain the
low prevalence of DH. Finally, our cohort did not include patients with farmer’s lung, in which the
presence of emphysema is classically described [51]. Studies with patients with subacute hypersensitivity
pneumonitis, cHP with obstructive disease and farmer’s lung are needed to elucidate the mechanisms
involved in reduced exercise capacity in such different populations.
In conclusion, reduced exercise capacity was prevalent in cHP patients, occurring in 50% of our cohort.
The primary causes of exercise limitations were found in ILD, such as ventilatory limitations and gas
exchange impairment with augmented dyspnoea. Despite significant involvement of small airways in cHP
patients, DH is infrequent during CPET, and without clinical repercussions. The main factor for preserved
exercise capacity in cHP is the ability to increase tidal ventilation, which is associated with preserved lung
function parameters. Patients with exercise impairment had lower physical functioning scores. Further
studies are necessary in cHP patients to fully understand the mechanisms involved in the development of
DH, and the role of interventions such as pulmonary rehabilitation in exercise capacity and QoL
improvement.
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